Study Finds Increased Risk of MGUS in Vietnam Vets Exposed to Agent Orange
the ONA take:
Vietnam War veterans exposed to Agent Orange, an herbicidal agent used for warfare, have more than a 2-fold increased risk for monoclonal gammopathy of undetermined significance (MGUS), according to a new study published online ahead of print in JAMA Oncology.
MGUS is a precursor to multiple myeloma. Patients with MGUS have lower antibody levels, plasma cells in the bone marrow, and no symptoms. Therefore, no treatment is indicated for patients with MGUS, but patients should be followed up every 6 months to determine if MGUS has transformed into multiple myeloma or a similar lymphoproliferative disorder.
For the study, a team of researchers led by Ola Landgren, MD, PhD, of Memorial Sloan Kettering Cancer Center in New York analyzed samples from 958 male veterans of the Vietnam War. Half of those were Operation Ranch Hand veterans who participated in aerial Agent Orange spray missions.
"Our findings of increased MGUS risk among Ranch Hand veterans support an association between Agent Orange exposure and multiple myeloma," the study concludes.
Agent Orange was widely used during the Vietnam War.
- Health Care Expansion Tied to Increased Rates of Surgical Treatment of Thyroid Cancer
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Hormone Refractory Prostate Cancer Responds to Abiraterone Acetate in Some Cases
- Beans, Whole Grains in Diet Beneficial for Colorectal Cancer Survivors
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Rubraca Granted Accelerated FDA Approval for Advanced BRCA-positive Ovarian Cancer
- New Criteria for Appropriate Use of Bone Scintigraphy to Diagnose and Manage Prostate and Breast Cancer
- Primary Care Physicians Surveyed on Breast Cancer Screening Practices
- Low Acculturated Latina Women Reported Breast Cancer Treatment Experience Differently Than Other Groups
- Cost and Complication Rates Differ Among Early Breast Cancer Treatment Options
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|